Immutep Limited
NASDAQ:IMMP · NASDAQ Global Market
+$0.00 today
Vol 0.23M · Avg 13.46M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.8%
avg -59.6%
ROIC
-86.9%
avg -54.9%
ROA
-39.1%
avg -48.0%
Analysis
ROA is currently the strongest return metric at -39.1% versus its period average of -48.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marc Voigt | Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director | $600,603.00 | — | 53 | $0.00 | <0.01% |
Frederic Triebel | Chief Scientific Officer & Executive Director | $496,414.00 | — | 71 | $0.00 | <0.01% |
Stephan Winckels | Chief Medical Officer | $478,170.00 | — | — | $0.00 | <0.01% |
Deanne Miller | Chief Operating Officer, General Counsel & Joint Company Secretary | $366,149.00 | — | 49 | $0.00 | <0.01% |
Christian Mueller | Chief Development Officer | $275,326.00 | — | — | $0.00 | <0.01% |
Indira Naidu | Joint Company Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +11.2% | +50.7% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +11.2% over three years. Forward estimates point to Revenue at +50.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.32B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$503.11M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$501.76M
Cabaletta Bio, Inc.
NASDAQ:CABA
$475.30M
Candel Therapeutics, Inc.
NASDAQ:CADL
$463.64M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$351.49M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$272.13M
Editas Medicine, Inc.
NASDAQ:EDIT
$257.97M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$202.50M
Mereo BioPharma Group plc
NASDAQ:MREO
$51.30M
Who manages IMMP?
Immutep Limited (IMMP) lists 6 active executives. The top listed executive is Frederic Triebel, Chief Scientific Officer & Executive Director.
Are IMMP insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.